Recombinant Group B Streptococcus Beta C Protein and a Variant with the Deletion of Its Immunoglobulin A-Binding Site Are Protective Mouse Maternal Vaccines and Effective Carriers in Conjugate Vaccines

ABSTRACT Immunogenic vaccines against group B Streptococcus (GBS) have been created by coupling the GBS capsular polysaccharides (CPS) to carrier proteins. The GBS beta C protein (BCP) serves as an effective carrier while inducing protective immunity against BCP-expressing strains. BCP also binds human immunoglobulin A (IgA), a characteristic that may be undesirable for use in humans. Here, we examined the immunogenicity and protective efficacy of a recombinant GBS BCP (rBCP), an rBCP modified to eliminate its IgA-binding site (rBCPΔIgA), and their corresponding GBS serotype III CPS conjugates (III-rBCP and III-rBCPΔIgA). Deletion of the IgA-binding site or conjugation to CPS did not alter antigenic BCP epitopes. Recombinant proteins and conjugates elicited specific, high-titered IgG in mice. Antisera to rBCP, rBCPΔIgA, III-rBCP, and III-rBCPΔIgA opsonized GBS strains A909 (Ia/BCP+) and H36B (Ib/BCP+) for killing by HL-60 cells; antiserum to III-rBCP and III-rBCPΔIgA also opsonized strain M781 (III/BCP−). Vaccination of female mice with either rBCP or rBCPΔIgA protected ∼40% of their pups challenged with GBS strain A909. Pups born to III-rBCP- or III-rBCPΔIgA-vaccinated dams survived at rates of 56% and 66%, respectively. Over 90% of pups born to dams that received the type III CPS conjugates survived challenge with GBS strain M781. In summary, rBCP and rBCPΔIgA proteins and the conjugates containing them were immunogenic in mice, inducing both CPS- and protein-specific functional IgG. These results suggest that the rBCPΔIgA could be used as a carrier to augment the immunogenicity of the CPS while expanding coverage to GBS strains bearing BCP.

[1]  L. Madoff,et al.  Group B Streptococcus bacteremia elicits beta C protein-specific IgMand IgG in humans. , 2007, The Journal of infectious diseases.

[2]  R. H. Albert,et al.  Prevention of perinatal group B streptococcal disease. Revised guidelines from CDC. , 2010 .

[3]  R. Rappuoli,et al.  Group B Streptococcus: global incidence and vaccine development , 2006, Nature Reviews Microbiology.

[4]  Diphtheria.  Division of Bacterial and Mycotic Diseases , 2006 .

[5]  G. Lindahl,et al.  Surface Proteins of Streptococcus agalactiae and Related Proteins in Other Bacterial Pathogens , 2005, Clinical Microbiology Reviews.

[6]  P. Larsson,et al.  Serotypes and clinical manifestations of invasive group B streptococcal infections in western Sweden 1998-2001. , 2004, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[7]  D. Kasper,et al.  Immune response of healthy women to 2 different group B streptococcal type V capsular polysaccharide-protein conjugate vaccines. , 2004, The Journal of infectious diseases.

[8]  Diminishing racial disparities in early-onset neonatal group B streptococcal disease--United States, 2000-2003. , 2004, MMWR. Morbidity and mortality weekly report.

[9]  D. Kasper,et al.  Glycoconjugate vaccines to prevent group B streptococcal infections , 2003, Expert opinion on biological therapy.

[10]  C. Baker,et al.  Group B streptococcal conjugate vaccines , 2003, Archives of disease in childhood.

[11]  Stephanie Schrag,et al.  Prevention of Perinatal Group B Streptococcal Disease Revised Guidelines from CDC , 2002 .

[12]  G. Lindahl,et al.  Streptococcal β Protein Has Separate Binding Sites for Human Factor H and IgA-Fc* , 2002, The Journal of Biological Chemistry.

[13]  D. Kasper,et al.  Quantitative determination of immunoglobulin G specific for group B streptococcal beta C protein in human maternal serum. , 2002, The Journal of infectious diseases.

[14]  R. Collier,et al.  Preclinical evaluation of group B streptococcal polysaccharide conjugate vaccines prepared with a modified diphtheria toxin and a recombinant duck hepatitis B core antigen. , 2001, Vaccine.

[15]  D. Kasper,et al.  Effects of Alum Adjuvant or a Booster Dose on Immunogenicity during Clinical Trials of Group B Streptococcal Type III Conjugate Vaccines , 2001, Infection and Immunity.

[16]  C. Frasch,et al.  Quantification of bacterial polysaccharides by the purpald assay: measurement of periodate-generated formaldehyde from glycol in the repeating unit. , 2001, Analytical biochemistry.

[17]  K. O’Connor.  Group B Streptococcal Disease in the Era of Intrapartum Antibiotic Prophylaxis , 2001 .

[18]  S. Olmsted,et al.  Antibody against Surface-Bound C5a Peptidase Is Opsonic and Initiates Macrophage Killing of Group B Streptococci , 2001, Infection and Immunity.

[19]  G. Lindahl,et al.  Streptococcal IgA-binding Proteins Bind in the Cα2-Cα3 Interdomain Region and Inhibit Binding of IgA to Human CD89* , 2001, The Journal of Biological Chemistry.

[20]  I. Charlebois,et al.  Identification of Group B Streptococcal Sip Protein, Which Elicits Cross-Protective Immunity , 2000, Infection and Immunity.

[21]  Marjolein van Egmond,et al.  FcαRI-positive liver Kupffer cells: Reappraisal of the function of immunoglobulin A in immunity , 2000, Nature Medicine.

[22]  A. Schuchat,et al.  Group B streptococcal disease in the era of intrapartum antibiotic prophylaxis. , 2000, The New England journal of medicine.

[23]  D. Kasper,et al.  Synthesis and preclinical evaluation of glycoconjugate vaccines against group B Streptococcus types VI and VIII. , 1999, The Journal of infectious diseases.

[24]  C. Leclerc,et al.  Reduced Response to Multiple Vaccines Sharing Common Protein Epitopes That Are Administered Simultaneously to Infants , 1998, Infection and Immunity.

[25]  A. Schuchat,et al.  Serotype distribution of invasive group B streptococcal isolates in Maryland: implications for vaccine formulation. Maryland Emerging Infections Program. , 1998, The Journal of infectious diseases.

[26]  F. Michon,et al.  Combination conjugate vaccines against multiple serotypes of group B streptococci. , 1997, Advances in experimental medicine and biology.

[27]  R. Leclercq,et al.  Streptococci and the Host , 1997, Advances in Experimental Medicine and Biology.

[28]  D. Kasper,et al.  Immune response to type III group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine. , 1996, The Journal of clinical investigation.

[29]  G. Lindahl,et al.  Experimental vaccination against group B streptococcus, an encapsulated bacterium, with highly purified preparations of cell surface proteins Rib and alpha , 1996, Infection and immunity.

[30]  K. Timmis,et al.  Identification of an immunoglobulin A binding motif located in the beta-antigen of the c protein complex of group B streptococci , 1996, Infection and immunity.

[31]  L. Paoletti,et al.  Cell growth rate regulates expression of group B Streptococcus type III capsular polysaccharide , 1996, Infection and immunity.

[32]  D. Kasper,et al.  Maternal immunization of mice with group B streptococcal type III polysaccharide-beta C protein conjugate elicits protective antibody to multiple serotypes. , 1994, The Journal of clinical investigation.

[33]  G. Lindahl,et al.  Protein rib: a novel group B streptococcal cell surface protein that confers protective immunity and is expressed by most strains causing invasive infections , 1993, The Journal of experimental medicine.

[34]  D. Kasper,et al.  Protection of neonatal mice from group B streptococcal infection by maternal immunization with beta C protein , 1992, Infection and immunity.

[35]  A. Schuchat,et al.  Group B streptococcal disease in the United States, 1990: report from a multistate active surveillance system. , 1992, MMWR. CDC surveillance summaries : Morbidity and mortality weekly report. CDC surveillance summaries.

[36]  D. Kasper,et al.  Immunogenicity in animals of a polysaccharide-protein conjugate vaccine against type III group B Streptococcus. , 1990, The Journal of clinical investigation.

[37]  D. Kasper,et al.  Immunization of pregnant women with a polysaccharide vaccine of group B streptococcus. , 1989, The New England journal of medicine.

[38]  E. Gotschlich,et al.  A surface receptor specific for human IgA on group B streptococci possessing the Ibc protein antigen , 1984, The Journal of experimental medicine.

[39]  D. Kasper,et al.  Correlation of maternal antibody deficiency with susceptibility to neonatal group B streptococcal infection. , 1976, The New England journal of medicine.